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Summary
Therapy of advanced melanoma has been changing dramatically. Following mutational and 
biological sub-classification of this heterogeneous cancer, several targeted and immune therapies 
were approved and increased survival significantly. To facilitate further advancements through pre-
clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) and live 
tissue samples from 384 patients representing the full spectrum of clinical, therapeutic, mutational, 
and biological heterogeneity of melanoma. PDX have been characterized using targeted 
sequencing and protein arrays, and are clinically annotated. This exhaustive live tissue resource 
includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-
responders to immune checkpoint blockade, and 31 samples from brain metastasis. Uveal, 
mucosal, and acral subtypes are represented as well. We show examples of pre-clinical trials that 
highlight how the PDX collection can be used to develop and optimize precision therapies, 
biomarkers of response, and the targeting of rare genetic subgroups.
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INTRODUCTION
Advanced melanoma has gone from limited therapeutic options to approved kinase inhibitor 
and immune checkpoint therapy. Five-year survival rates have nearly doubled (Menzies et 
al., 2015; Schadendorf et al., 2015). Precision medicine and immune oncology are major 
areas of translational melanoma research. The complex melanoma landscape needs 
improved models reflecting all mutational and clinical subtypes. The UV carcinogenic 
etiology of melanoma makes it one of the most highly mutated cancers (Alexandrov et al., 
2013). This high mutational burden may be the reason for the success of immune checkpoint 
blockade (Callahan et al., 2016), but makes rational “precision” therapies challenging 
(Krepler et al., 2016).
The Melanoma Cancer Genome Atlas (TCGA) includes comprehensive molecular 
characterization of 333 non-acral cutaneous melanomas and is an important resource. It 
confirmed the main mutational subgroups of BRAF, NRAS, NF1, and triple wild type, as 
well as highlighting the distinct heterogeneity and high mutational burden of melanoma 
(Cancer Genome Atlas, 2015). Subtypes not included in the TCGA but published elsewhere 
were uveal (Van Raamsdonk et al., 2010), acral cutaneous (Furney et al., 2014), and mucosal 
melanoma (Sheng et al., 2016).
Patient-derived xenografts (PDX) as xenotransplantation of human tumors into athymic nude 
mice were first described by (Rygaard and Povlsen, 1969). PDX are established directly 
from patient tumors in immune deficient mice and thus provide a source of tumor tissue 
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closely resembling the clinical lesion (Hidalgo et al., 2014). Melanoma is uniquely suited to 
this approach as even single cells are tumorigenic in vivo (Quintana et al., 2008). Melanoma 
PDX were shown to accurately model the clinical disease and response to targeted therapy 
(Einarsdottir et al., 2014). We have shown recently that PDX derived from BRAF inhibitor 
relapsed patients and expanded on chronic therapy could be used to identify effective second 
line combination therapies based on genomic and proteomic profiling (Krepler et al., 2016). 
While these studies demonstrate the feasibility of the PDX approach, the melanoma TCGA 
and other studies (Arafeh et al., 2015; Cancer Genome Atlas, 2015; Krauthammer et al., 
2015) highlight the pronounced heterogeneity of this cancer type. Both concepts are 
combined here in an unparalleled collection of 459 mutationally and clinically diverse 
melanoma PDX and live frozen tissues, providing an exhaustive and testable resource for the 
melanoma research field. This resource is highly clinically annotated, includes rare body 
sites and subtypes such as brain metastasis, uveal, mucosal, and acral melanoma, as well as 
pre- and post-therapy samples from targeted inhibitor and checkpoint blockade treated 
patients.
RESULTS
Establishment of Melanoma PDX
We have collected 694 melanoma samples for PDX generation from eight institutions 
(Figure 1A). Fresh tumor samples were either directly implantated within 24 hours 
subcutaneously (s.c.) in NOD/SCID/IL-2Rγnull (NSG) mice or banked as cryopreserved 
live tissue (Figure 1A). Keeping primary tissue in a live tumor bank was a cost-effective 
alternative to fresh implantation, but dependent on adequate amounts of tissue. Both 
approaches successfully established PDX and detailed methods are included in the 
experimental procedures section and in a standard operating procedures (SOP) handbook 
(Supplementary File S1).
Of the samples collected, 319 were established as PDX and 140 were banked as live primary 
tissue w (Figure 1B) totaling 459 models from 384 different patients. Failure to establish a 
PDX was due to sample contamination, unexpected death of a primary recipient animal, 
receipt of non-viable samples, or non-melanoma samples (Figure 1B). Thus, although the 
overall success rate for establishing melanoma PDX was 62%, the take rate corrected for 
these factors was 83% (Figure 1C). This excluded primary uveal samples whose take rate 
was 11%.
Time to Tumor Growth and Tumor Growth Rate
Tumor samples were obtained from either fine needle aspirates (FNA), core biopsies, or 
surgical excisions. We found no significant difference in latency (time from implantation to 
palpable tumor) and tumor growth rates (time to maximal tumor size) (Figure 1D,E).
Very Small Cell Numbers Are Needed to Establish a Melanoma PDX
Tissues from three patients were enzymatically digested and hematopoietic cells, red blood 
cells, and endothelial cells removed We observed consistent tumor engraftment in mice at 
1000, 100, 10, and 1 cell(s)/mouse (Figure 1F). The latency period was extended by up to 4 
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months indicating that a follow up of 6 months is optimal to achieve maximum engraftment. 
Further, tumorigenicity did not significantly change when sorting the cells for the cancer 
stem cell marker CD271 (Boiko et al., 2010) (Figure 1G).
Patient Demographics Reflect the Clinical Spectrum of the Disease
Patients’ age ranged from 20–89 years with a peak between 60–69 years (Figure 2A)with a 
predominance of male patients, likely representing our sampling bias for advanced disease 
(Geller et al., 2002) (Figure 2B). More than 80% of patients had stage IV disease. The 
largest proportion of samples (68%) was metastases from patients with non-acral cutaneous 
primaries (Figure 2C), but we also included 59 unknown primary, 17 mucosal, 15 acral 
cutaneous, and 10 uveal melanomas. Approximately 44% were subcutaneous (Figure 2D) 
and 26% lymph node metastasis samples, since these are often excised for diagnostic or 
therapeutic reasons. Remarkably, 23% were distant organ metastates, including brain. 
Primary melanomas represented 5%, although these were thick primaries and the patients 
had often already developed stage III disease.
Our collection spanned several years and the therapies for advanced melanoma have evolved 
during that period. Samples therefore reflect the standard of care and ongoing clinical trials 
at contributing centers, ranging from untreated through targeted therapy, to immune 
checkpoint blockade, and combination therapies (Figure 2E).
Genomic Characterization and Clinical Annotation
The majority (n=314, 68%) of PDX and tissues were analyzed for genomic alterations using 
massively parallel sequencing of a 108-gene targeted panel. The genes included in this panel 
were selected based on previously described mutations and copy number variations in 
melanoma. A full list of included genes and an in-depth analysis of mutational and copy 
number data of all PDX models as well as additional melanoma cell lines (n=488 total) are 
described in a companion resource article (Garman et al., 2017). An additional 90 patients 
were annotated by NGS targeted panels of 40–400 genes at their clinical institutions and we 
used these data to infer oncogenic driver mutation status of PDX. Both data sets were 
combined to classify a total of 372 PDX or banked tissues into major mutational subgroups.
Half (55%) of all samples analyzed were BRAF hotspot mutant, 20% NRAS mutant, 7% 
NF1 mutant, 2% KIT, 1.4% GNAQ/GNA11, and 18% wild-type (WT) (Figure 3A and 
Supplementary File S2). These results correlate with the melanoma TCGA data (Cancer 
Genome Atlas, 2015) and other published large scale sequencing studies (Arafeh et al., 
2015; Hodis et al., 2012; Krauthammer et al., 2015).
Thirty-seven of the BRAF hotspot mutation PDX were from patients progressed on a BRAF 
inhibitor (12 previously published in (Krepler et al., 2016) and 44 progressed on 
BRAF/MEK inhibitor combination therapy. We collected 190 samples from patients with 
immune checkpoint inhibitor therapy (anti CTLA4 and/or anti PD-1). These did not cluster 
to any mutational subgroup. We established PDX from patients progressed on both targeted 
and immune therapy (25 sequentially and 17 with BRAF inhibitor/PD-1 blockade 
combination therapy). (Figure 3A and Supplementary File S2)
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The reverse phase protein array (RPPA) platform quantified ~300 proteins and 
phosphorylated proteins. These profiles are a useful complementary analysis to genetic 
sequencing (Krepler et al., 2016) and are available for 113 PDX models while others are in 
progress (Figure 3A and Supplementary File S3
PDX derived cell lines
We have established cell lines from 24 PDX tumors with a focus on targeted therapy 
resistant and brain metastasis samples (Figure 3A). These are added to the 112 cell lines of 
the “Wistar Melanoma” collection (https://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/
page/melanoma-cell-lines-0). As these PDX derived cell lines included 10 derived from 
targeted therapy resistant samples, the mutational distribution is biased for BRAF hotspot 
(71%). Further, the cell lines include seven from brain metastasis, two acral melanoma 
(WM4324: V600E, WM4235: Q61R) and one mucosal (WM4173: WT/WT).
PDX from Patients Treated with Checkpoint Inhibitors
We established 190 PDX from 140 immune checkpoint blockade therapy patients. Best 
response was complete response in 7 patients, partial response in 26, mixed response in 5, 
stable disease in 10, and progressive disease in 59 patients. Response data could not be 
obtained in 33 patients. Forty-three patients received only anti CTLA4, and 50 received only 
anti PD-1; 41 patients received both therapies sequentially and six as a combination therapy. 
All patient samples were collected either before, on-, or after immune therapy with 16 
patients matched before and on or after therapy (Figure 3B).
PDX from Targeted Therapy Resistant Patients
We collected 57 biopsies from 47 patients after progression on BRAF or BRAF and MEK 
combination targeted kinase inhibitor therapy (either still on or shortly after end of therapy) 
(Figure 3C). After initial establishment and expansion as PDX, the tumor graft bearing 
animals were continuously dosed with BRAF inhibitor (PLX4720) or BRAF/MEK inhibitor 
(PLX4720/PD-0325901) combination diet corresponding to the type of therapy received by 
the patient (Krepler et al., 2016). Targeted sequencing of resistant PDX tumors using our 
108-gene panel (Garman et al., 2017) confirmed a BRAFV600 hotspot mutation in all but 
two of the models. These two PDX models were established from patients with clinical 
BRAFV600E positive tumors. However, the patient material tested for WM4323 was the 
primary cutaneous melanoma diagnostic biopsy accessioned 5 years prior to the specimen 
sent for PDX. This was done via pyrosequencing of codons 595 and 600 of exon 15 of the 
BRAF gene. The patient material tested for WM4352 was a metastatic lymph node 
accessioned 7 months prior to the specimen sent for PDX. This was done via NGS panel of 
50 genes including, for BRAF, codons 439–473 of exon 11 and codons 581–611 of exon 15.
Several mechanisms of resistance were revealed by targeted sequencing. We found 
concomitant RAS (n=7/47 patients) and MAP2K1/2 (n=9/47 patients) mutations. These 
deleterious mutations were mutually exclusive and have been reported previously as 
activating mutations conferring resistance to BRAF inhibition (Emery et al., 2009; Nazarian 
et al., 2010). BRAF high level amplification (>5) in four patients and MET high level 
amplification (>5) in three patients were exclusive of each other and RAS and MAP2K 
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activating mutations (Shi et al., 2013). PDX from 15 patients had alterations in the PI3K 
signaling pathway (13 PTEN deletion, 3 deleterious PTEN mutation, 5 likely deleterious 
PTEN mutation, 1 deleterious PIK3CA mutation) although these were not mutually 
exclusive with the other genomic changes observed.
Patient matched PDX from before start and after progression on targeted therapy were 
generated from seven patients. Of these, two (WM4298, WM4351) had acquired NRAS 
mutations on dabrafenib-trametinib combination therapy (D/T) and progressed after 406 and 
161 days respectively. WM3901 was established from a solitary progressing (>10%) s.c. 
metastasis after 480 days on D/T and had acquired a BRAF amplification. WM4264 had 
PFS of 120 days and an acquired MEK2K61E heterozygous mutation in the relapse PDX. 
Although a variant of unknown significance per our algorithm (Garman et al., 2017), due to 
the location and glutamic acid change this might be a phosphomimetic activating mutation 
(Villanueva et al., 2013). WM4070 PDX were established from the patient with the shortest 
PFS (60 days) and we found a pre-existing MEK1 mutation in both pre-and post- therapy 
PDX. The remaining two models (WM4276, WM4237) had pre-existing loss of PTEN and 
amplification of MET respectively as possible contributors to resistance (Figure 3C).
Protein expression profiles
RPPA was performed on a total of 118 PDX models in triplicate divided on two batches. Set 
102 (Supplementary File S3) had 184 profiles representing 60 models including one model 
with corresponding untreated and BRAF inhibitor treated samples. Set 119 ((Supplementary 
File S4) had 243 profiles containing 58 models, 23 of which have corresponding untreated 
and BRAFi and/or BRAFi/MEKi treated tumor samples. Set 102 assessed 279 phospho and 
total proteins, and set 119 assessed 299 phospho and total proteins.
PDX Derived from Brain Metastasis
We collected melanoma brain metastasis (MBM) tissue from 34 neurosurgeries of 28 
patients to generate PDX models. Targeted sequencing data are currently available for 20 
PDX and RPPA data for 12 (Figure 3D). Remarkably, four brain metastases were collected 
from the same patient (WM4237-1 to -4) at 2- to 4-month intervals. Although the patient had 
received dabrafenib/trametinib combination therapy (best response stable disease) after the 
first surgery, and had received anti PD-1 therapy during the last two surgeries, all four PDX 
had identical mutation profiles (BRAFV600E RB1N690fs TP53S241). PDX from seven 
patients had BRAF hotspot mutation and from six patients NRAS hotspot mutation. One of 
these had a co-occurring BRAF non-hotspot mutation. Another BRAF non-hotspot mutation 
was co-occurring with an NF1 mutation. Two patients were wild type for both BRAF and 
NRAS. Interestingly, the samples without BRAF hotspot mutation had significantly more 
concurrent deleterious and likely deleterious mutations overall. We found PTEN deletion or 
deleterious mutation in four of 7 patients with BRAF hotspot mutation which has been 
shown to be associated with MBM (Bucheit et al., 2014). On the protein expression level, 
both patients with deleterious PTEN mutations had evidence of PI3K pathway activation by 
relative increased phospho AKT compared to WT PTEN samples.
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PDX from Primary or Metastatic Uveal Melanoma Samples
We implanted 45 uveal primary samples as tumor fragments s.c. in the interscapular fat pad 
of NSG mice with matrigel (Némati et al., 2010). After follow up of at least 12 months, we 
observed tumor growth in five models, albeit kinetics were slow. Three of these had 
mutations in GNAQ or GNA11, one was WT, and one failed genomic analysis. In contrast, 
the take rate for metastatic samples from uveal melanoma patients was comparable to 
cutaneous melanoma and we established four samples as PDX, one with a GNAQ mutation, 
and the others in process.
Availability of PDX models to the research community
A critical component of our PDX platform is its availability to the research community. Like 
cell line repositories, PDX tissue can be frozen and expanded as needed. Thus, we made a 
representative pre-selection of 26 “work horses” based on genetic, and clinical criteria 
available through www.horizondiscovery.com/patient-derived-xenograft/melanoma-pdx 
(Supplementary File S2). All other models are available upon request and tissue will be 
expanded either at Horizon Discovery Inc. (St. Louis, MO) or our laboratory.
Spontaneous Metastasis Rate is Associated with Mutational Group
When cells from a PDX model were inoculated into a human skin graft on NSG mice (Li et 
al., 2015), tumors formed within the human dermis. These then metastasized out of the 
human graft into the lungs of host mice as an indicator for distant organ metastasis (Figures 
4A–C). This propensity to invade the mouse tissue and seed distant organs was reflected in 
the subsequently observed high rates of spontaneous metastasis in s.c. implanted PDX 
models. We analyzed lungs of mice at the time of tumor harvest (Figure 4D) and found that 
in 32% of PDX models assessed, more than 80% of the animals had micro- or macro-
metastases (Figure 4E). There was a significant increase in metastatic ability of BRAF 
hotspot mutant PDX and a decreased metastatic rate in triple WT PDX (Figure 4F).
Spontaneous brain metastasis model
An MBM derived PDX was established as a short-term culture, transfected with a luciferase 
reporter and implanted s.c. into NSG mice. To prolong survival of animals, primary tumor 
grafts were surgically removed once established (Figure 4G). We observed spontaneous 
metastasis to the mouse brain in 50% of animals after a latency of 120 days (Figure 4H). 
Additional such models are in development.
PDX tumors resistant to MAPK inhibitors have increased IGF1R expression
We assessed expression of a panel of melanoma surface receptors previously described as 
cancer stem cell markers including CD20 (Fang et al., 2005), CD271 (Boiko et al., 2010), 
and CD133 (Monzani et al., 2007) in two cohorts of therapy naïve and resistant PDX. There 
were no significant differences observed for any of the markers (data not shown). However, 
tumors derived from targeted therapy progressed patients had significantly higher levels of 
IGF-1R than tumors from therapy naïve patients (Figure 4I). IGF-1R/PI3K signaling has 
previously been implicated in conferring melanoma resistance to BRAF inhibitors 
(Villanueva et al., 2010). Interestingly, when the resistant tumor grafts were grown on 
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continuous BRAFi or BRAF/MEKi combination diet the IGF-1R levels returned to baseline 
(Figure 4I). This phenomenon might indicate the transient nature of tyrosine kinase receptor 
upregulation and its modulation by MAPK pathway inhibitors.
Predictive Value of PDX for Response to Targeted Therapies
We selected a PDX from a 55-year-old female patient with metastatic melanoma and early 
relapse to vemurafenib after partial response using RECIST 1.1 criteria and progression free 
survival of 16 weeks. Lymph node lesions in her right and left axillary regions showed initial 
on-treatment regression: there was a 70.6% decrease in the target lesion (i.e., the right 
axillary node) and a partial response in the non-target lesion (the left axillary node) (Figure 
5A). An FNA was taken from the left lymph node before therapy and used to generate a 
PDX. After in vivo expansion, tumor bearing animals were treated with the BRAF inhibitor 
PLX4720 alone and in combination with the MEK inhibitor PD-0325901. Tumors did not 
respond to BRAF inhibition, but regressed on BRAF/MEKi combination followed by 
relapse (Figure 5B). This was reflected in a reduced proliferation rate in the combination 
therapy tumor cells only (Figure 5C).
MEK and PI3K Beta Inhibition as Second-line Therapy in BRAF Inhibitor Resistant Models
We selected three BRAF-V600E PDX models derived from patients relapsed on BRAF 
inhibitor. Two had homozygous PTEN deletion and one had an activating NRASQ61K 
mutation; all showed activation of both MAPK and PI3K pathways on the protein level 
(Krepler et al., 2016). The MEK inhibitor trametinib and the PI3K beta/delta isoform-
specific inhibitor GSK418 (an analog of GSK2636771 (Rivero and Hardwicke) significantly 
decreased tumor growth in the two PDX models with PTEN deletion without evident 
toxicity (Figure 5D), but not in the PDX with concurrent BRAF and NRAS mutation.
ERK and MDM2 Inhibition Is Highly Effective in a BRAF Inhibitor-resistant PDX Model
WM3973 was derived from a patient progressed on vemurafenib with MAPK pathway 
reactivation via an activating MAP2K1 (MEK1) mutation as a potential resistance 
mechanism (Krepler et al., 2016). Accordingly, this PDX model did not respond to BRAF 
inhibition or even to the downstream targeting ERK inhibitor BVD-523. We then applied a 
previously published response biomarker signature for p53 re-activation (Jeay et al., 2015) to 
a cohort of nine TP53 wild type BRAF inhibitor resistant PDX models. The majority 
including WM3973, were predicted sensitive to MDM2 inhibition (data not shown). The 
MDM2 inhibitor CGM097 (Holzer et al., 2015) moderately inhibited WM3973 tumor 
growth as a single agent, but ERK and MDM2 inhibition synergized potently to induce 
stable disease over 6 weeks of dosing (Figure 5E, left panel).
Typical of the tumor growth heterogeneity seen in PDX experiments, single mice showed a 
variable response to the combination therapy (Figure 5E, right panel). Whereas most animals 
had stable disease, two tumors showed early relapse, and two tumors had complete 
responses at the end of dosing. Both regrew only after treatment was stopped, confirming 
that in PDX models small residual tumors can survive following several weeks of drug 
pressure. However, we did not observe any tumors acquiring resistance while on 
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combination therapy, indicating that this approach could be explored further using additional 
models.
We analyzed protein expression profiles of tumor grafts at the end of dosing to investigate 
the heterogenous responses seen with this therapy. The clusters from unsupervised 
hierarchical clustering identified groups that were predominately based on proteins with a 
role in proliferation and correlated with tumor growth rates rather than dosing groups 
(Supplementary Figure S1). The BVD-523 single agent group whose tumors grew at the 
same rate as controls, clustered with the fastest growing tumors in the control group, 
indicating that ERK inhibition alone did not widely change the protein and phospho protein 
levels assessed in this array. Indeed, there was no inhibition of pERK on RPPA. However, 
the BVD-523 single agent group had the least tumor growth variability with all tumors 
progressing rapidly. All tumors with continued response to combination treatment clustered 
in one group, whereas the two tumors with early resistance to the combination therapy 
clustered with the CGM single agent samples.
Rapid in Vivo Screen for BET Inhibitor Activity in a Broad PDX Panel
We used the novel BRD4 inhibitor BAY8097 to conduct a rapid in vivo screen on 20 PDX of 
diverse mutational profiles. To test feasibility, we reduced group size from 10 to 3 mice per 
group. Like the model in Figure 3E, we observed significant heterogeneity in tumor growth, 
a problem also encountered in a recently published study using only one tumor graft/PDX/
therapy (Gao et al., 2015). We found that a subset of models not clustering into a mutational 
subgroup showed significant tumor growth inhibition using BAY8097 as a single agent 
(Figure 5G).
Validation of Increased Onco-metabolites in PDX with IDH1 Mutation
We identified eight PDX with the canonical IDH1 mutation R132C. Only one melanoma cell 
line with very slow growth kinetics has been described in the literature (Lopez et al., 2010). 
Indeed, we were unsuccessful in establishing cell lines from these patient samples (data not 
shown). We tested levels of the D-2-hydroxyglutarate (2-HG) onco-metabolite (Mondesir et 
al., 2016) and confirmed buildup to very high levels as compared to WT in PDX tissue 
(Figure 5H).
PDX Can Model Pathway Adaptation to Targeted Drugs Over Time
To assess the potential of PDX models to mimic acquired drug resistance, we performed a 
time course analysis of response and acquired resistance to a BRAF inhibitor in a targeted 
therapy-naïve BRAF-V600E PDX. The patient had received BRAF inhibitor therapy after 
the biopsy was taken and initially responded followed by relapse after 9 months. Although, 
the patient never received BRAF/MEK combination therapy, we followed up with this 
combination in our PDX model (Figure 6A). The PDX tumors initially responded to BRAF 
inhibition with almost complete tumor regression but relapsed after seven weeks; however, 
when the same animals were switched over to BRAF/MEK inhibitor combination they again 
responded continuously without relapse for up to 2.5 months. Tumors from each treatment 
were analyzed for protein expression by RPPA in a time course manner (Figure 6B, full 
dataset in Supplementary File S5). Protein expression only changed significantly with the 
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onset of BRAF inhibitor resistance (Figure 6C), and the subsequent change to BRAF/MEK 
inhibitor combination therapy shut down cell proliferation, induced apoptosis and led to 
sustained tumor growth inhibition (Figure 6D). Thus, PDX models can be used to track 
changes in tumor cell signaling on the protein level over the course of therapy.
DISCUSSION
Established melanoma cell lines have significant bias toward BRAF, TP53 mutations, and 
CDKN2A loss (Garman et al., 2017) since these adapt well to in vitro growth. The much 
higher success rate of PDX irrespective of mutational subgroup make PDX more clinically 
relevant (Byrne et al., 2017; Townsend et al., 2016). Several other research groups have 
established melanoma PDX models (Einarsdottir et al., 2014; Gao et al., 2015; Girotti et al., 
2016; Kemper et al., 2016; Quintana et al., 2012). Quintana et al. established PDX from 25 
stage IIIB/C patients and correlated spontaneous metastasis in the animals with patient 
outcome. Einarsdottir et al. established PDX from 23 patients and predicted targeted therapy 
responses in a subset. Gao et al. employed a 1×1×1 in vivo trial design in 277 PDX 
including 67 melanoma derived, demonstrating clinical translatability of this approach. 
Kemper et al. established 89 PDX, but focused on BRAF mutant patients with only 10 
NRAS and 6 WT/WT samples. They then used this platform to identify a novel resistance 
mechanism to BRAF inhibition in the form of a duplicated kinase domain. Girotti et al. have 
built a collection of about 90 PDX models, of which they show 3 deeply characterized 
examples by following the development of resistance to targeted therapy over time using 
whole exome sequencing. Together, these studies show the promise and potential of PDX 
models in melanoma.
Multiple resistance mechanisms to targeted therapy have been described and these most 
often lead to re-activation of the MAPK pathway or activation of alternative pathways such 
as the PI3K signaling pathway (Rizos et al., 2014). Pre-clinical data by several groups have 
suggested that combining BRAF/MEK inhibitors with PI3K/mTOR inhibitors may 
overcome resistance in BRAF mutant melanomas (Atefi et al., 2011; Greger et al., 2012; 
Shannan et al., 2016; Villanueva et al., 2010). Phase I clinical trials using this combination 
demonstrated the safety of this combination approach and some early signs of clinical 
activity (Bedard et al., 2012; Juric et al., 2014), and further phase I/II trials are ongoing 
(NCT01449058, clinicaltrials.gov). On the other hand, a Phase I trial testing the combination 
of pan-PI3K/mTORC1/2 inhibitor GSK2126458 with trametinib was terminated due to a 
lack of tolerability and efficacy (NCT01248858), suggesting a narrower targeting profile 
might be advantageous. Thus, our pre-clinical PDX trial confirmed that combination of a 
beta isoform specific PI3K inhibitor retained synergistic potential with MEK inhibition but 
could potentially decrease toxicity.
We included PDX with diverse mutational backgrounds that were either naïve or progressed 
on targeted therapy in an in vivo screen of a novel BET inhibitor. Targeting the 
transcriptional activity of cancer cells has emerged recently as a novel strategy 
(Filippakopoulos et al., 2010). It is unclear however, which patients would benefit from 
these inhibitors and whether it would be a viable strategy in a clinical setting for melanoma 
(Segura et al., 2013). Our PDX collection is large enough to mirror the diversity of patients 
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that would be studied in an early-stage clinical trial at a fraction of the cost and could be 
beneficial for early-stage drug screening as well as for the development of biomarkers. The 
activity of BET inhibition seen in a subset of PDX models, although hampered by high 
heterogeneity, still warrants further investigation into this class of compounds and use of the 
PDX data to identify response biomarkers.
Another strength of our large collection of PDX is the breadth of coverage including 
multiple samples with rare mutations, made possible by large-scale targeted sequencing of 
PDX (Garman et al., 2017). IDH1 is a rarely mutated oncogene in melanoma, representing 
about 6% of driver mutations (Cancer Genome Atlas, 2015) and has been described as a 
viable target in other cancers (Tateishi et al., 2015). Since PDX are a living resource we 
could functionally validate the mutation by assessing the accumulation of the onco-
metabolite 2-HG in the tumor grafts. Thus, these models would be ideal to test inhibitors of 
IDH1.
MBM is a common event in late stage patients and has a poor prognosis of less than one 
year median survival (Staudt et al., 2010) even with modern systemic therapies (Forschner et 
al., 2017). Although current targeted and immune therapies have demonstrated activity in 
MBM, successful therapy is still a major challenge and an important area of current 
investigation (Glitza Oliva et al., 2017). MBM models are scarce and new therapies are 
needed urgently. Thus, we focused our collection efforts on samples derived from MBM and 
these will provide a valuable resource to study this challenging to treat and frequently lethal 
manifestation of late stage melanoma.
Although patients can show long-lasting responses to immune checkpoint blockade, many 
patients do not respond or acquire resistance. Clinical studies point towards the importance 
of the immune infiltrate in tumors (Chen et al., 2016), however human tumor-infiltrating 
lymphocytes implanted with the initial patient tumor tissue are lost in PDX propagation. 
High mutational load is associated with increased response rates to immune therapies with 
neo-antigens the target of immune responses (Peng et al., 2016). Thus, PDX models from 
checkpoint inhibitor responders and non-responders could potentially be valuable tools to 
study the role of tumor biology in response to immune therapy and we are currently 
investigating neo-antigens. Our collection of PDX can be used to study checkpoint inhibitors 
or other immune therapies alone or in combination with targeted kinase inhibitors when 
employed in humanized mouse models (unpublished). In these models, human CD34+ 
hematopoietic stem cells are injected to reconstitute human B and T cells in NSG mice 
(Rongvaux et al., 2014). Thus, the current limitations of model could potentially be 
addressed using humanized mice and would allow PDX models to be at the forefront of 
immune and targeted therapy translational research (Sanmamed et al., 2016). These studies 
are ongoing.
In summary, we have built a unique and comprehensive melanoma PDX collection 
representing the entire spectrum of this cancer with multiple biological replicates even for 
rare subgroups. It is further enhanced through genetic and genomic analysis in our 
companion paper (Garman et al., 2017).
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EXPERIMENTAL PROCEDURES
Detailed SOPs for all aspects of PDX generation and use are provided in Supplementary File 
S1.
Patient sample processing
Patient samples were collected under IRB approval. Tumor samples were processed within 
24 hours of biopsy. Samples were mechanically dissociated and enzymatically digested if 
necessary. Tumor tissue was frozen in 10%DMSO 90%FBS, if sufficient quantities were 
available, or implanted directly into NSG mice. Mice were anesthetized, a small skin 
incision (~5mm) was made in the back of the animal, and a subcutaneous pocket created. 
Tumor fragments were implanted with 100 μL of matrigel, and the incision closed with a 
wound clip.
PDX Maintenance
All animal experiments were performed in accordance with institutional guidelines under 
Wistar IACUC approval. PDX were expanded in NSG mice. Tumor size was assessed once 
weekly by caliper measurements (lengthxwidth2/2). Animals were sacrificed when the 
tumors reached 1,000mm3 or when necessary for animal welfare. The larger part of the 
tumor was retained as a live tumor bank, the smaller part was re-implanted at 1:5 ratio. PDX 
tumors from patients progressed on BRAF or BRAF/MEK inhibitor therapy were expanded 
on continuous PLX4720 200ppm or PLX4720 200ppm + PD-0325901 7ppm chemical 
additive diet (Research Diets, New Brunswick, NJ).
Pre-clinical in vivo trials
When tumors reached 200mm3, mice were randomized into treatment groups. Groups in the 
efficacy studies were 10 animals each to account for variability among tumors, except for the 
BAY8097 rapid in vivo screen which was designed with three animals/group. Tumor sizes 
were assessed twice weekly per caliper measurement, and tumor volume was estimated 
using the formula (lengthxwidthxwidth/2). Mice were sacrificed after 2–3 weeks of 
treatment. If therapy groups showed tumor regression, dosing was prolonged.
Short Tandem Repeat (STR) Profiling
We performed STR profiling on one tumor per MP using AmpFlSTR® Identifiler® PCR 
Amplification Kit (Life Technologies, Carlsbad, CA) which uses loci consistent with all 
major worldwide STR standards. Genomic DNA was extracted from patient or xenograft 
tumor samples using DNeasy® Blood & Tissue Kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. PCR amplification and STR allele separation and sizing was 
performed by the Wistar Genomics Facility. Profile interpretation was performed in our lab 
by interrogating the resulting DNA fingerprint to our internal database which includes over 
1,000 fingerprints and is available on our website www.wistar.org/lab/meenhard-herlyn-
dvm-dsc/page/melanoma-cell-str-profiles. DNA fingerprinting was matched to normal blood 
DNA if available to confirm identity of the samples.
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Massively Parallel Sequencing
DNA from patients and/or PDX were characterized by massively parallel sequencing using a 
custom-designed 108 gene targeted panel. Results were annotated for mutations, insertions 
and deletions, and copy number changes. A detailed description of the methodology and 
analysis is provided in (Garman et al., 2017). Briefly, DNA was purified (DNeasy Blood & 
Tissue Kit), 500 ng of genomic DNA was sheared randomly into 200 bp fragments, and 
sheared DNA was A-tailed and ligated with adaptor-embedded indexes using the 
NEBNext® UltraTM DNA Library Prep Kit for Illumina® (New England BioLabs, Inc., 
Ipswich, MA). Samples were equimolarly pooled prior to capture with a 2.2 Mbp 
SureSelectXT Custom Target Enrichment Kit (Agilent Technologies, Santa Clara, CA) 
targeting 108 genes previously implicated in melanomagenesis. Paired-end (2X100 bp) 
sequencing was performed on the HiSeqTM 2000 sequencing system (Illumina, Inc., San 
Diego, CA).
To account for mouse DNA contamination, previously unreported variants with an allelic 
fraction of less than 0.15 were filtered out of the analysis.
Foreskin Grafting Procedure
Prepared rectangles of about 1.5 × 2 cm foreskin were placed on skin defects on the back of 
a mouse with the panniculus canosum remaining intact. The panniculus canosum was 
needed to help vascularize the graft. The foreskin graft was then secured in situ using 
Tegaderm (3M, St. Paul, MN). After 10 days, the dressing was removed and the graft was 
fully healed in 5–6 weeks.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections of xenograft tumors were cut into 4 μm 
sections, deparaffinized in xylene, rinsed in ethanol and rehydrated. Then, the tissues were 
stained with Ki-67 mouse clone MiB-1 (Dako, Carpinteria, CA; Catalog# M7240).
Flow Cytometry Staining
Tumors were analyzed after mechanical dissociation followed by filtration and red blood cell 
lysis. For surface staining, cells were incubated at 4°C for 30 minutes with anti-human 
PeCy7 CD146 (M-CAM), anti-mouse FITC- CD45, H2Kb and H2Kd and anti-human PE 
IGFR1 from BD Biosciences (San Jose, CA). Staining were performed in presence of LIVE/
DEAD® Fixable Dead Cell Stains (Life Technologies). After dead cells and mouse cell 
exclusion, percentage of double positive CD146 and IGF1R cells were reported.
RPPA
The samples were prepared as previously described (Krepler et al., 2016). RPPA was 
performed by the MD Anderson Center RPPA core facility (Houston, TX) as previously 
described (Tibes et al., 2006). Unsupervised hierarchical clustering using centered 
correlation and complete linkage was performed on normalized log2 median-centered 
protein values using Cluster 3.0 software (http://bonsai.hgc.jp/~mdehoon/software/cluster/
software.htm#ctv). Results were visualized using Java TreeView 3.0 software (http://
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jtreeview.sourceforge.net). For WM4007 time course analysis, normalizedLog2 values were 
median centered to the average of the untreated controls. The three tumors from each time 
point were averaged. K means clustering using Euclidean distance measure on 10 clusters 
(identified in unsupervised hierarchical clustering) run for 100 iterations was performed 
using Cluster 3.0 and visualized with Java TreeView. Clusters with variance greater than 
0.10 across the time points were selected for Gene Ontology analysis using Ingenuity 
Pathway Analysis (Qiagen) for biological processes.
Statistical Analysis
The scatter plots with mean of multiple mice’s tumor growth rates were reported by FNA, 
core, and excisional biopsy patient samples, or by patient’s sample. Shapiro normality tests 
were used to examine the distribution of studied variables. Non-parametric Mann-Whitney 
tests were used for between specific gene mutant group comparison. Linear mixed-effect 
models were used to test the difference of the tumor growth trends among treatment groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Establishment and biology of PDX models
(A) A total of 694 melanoma tissue samples from naïve, pre-, on-, or post- therapy time 
points receiving targeted kinase inhibitors (TT) or immune checkpoint inhibitors (IT) were 
used to generate PDX and/or banked as live tissue. (B) Success rate of establishing a tumor 
graft (green), banking of live tissue with the potential of establishing a PDX or 
establishment in progress (blue), no tumor growth at 6 to 12 months (orange), adverse events 
(gray) where we were not able to establish a PDX due to reasons other than tumor take (this 
analysis excludes uveal primary samples). (C) Take rate of cutaneous melanoma derived 
tissue. (D) Time to palpable for all FNA, core, and excisional biopsy patient samples. (E) 
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Tumor growth rate comparison of FNA, core, and biopsies. Growth was calculated as tumor 
volume/weeks. (F) Fresh tumor biopsies (MP0) or PDX after MP1 from three patients were 
prepared as cell suspensions, leucocytes and endothelial cells excluded and injected s.c. into 
NSG mice at indicated cell numbers. (G) Single cell suspension was prepared as before and 
sorted for CD271 marker. CD271+ and negative cells were injected at indicated cell 
numbers.
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Figure 2. Demographics of patient samples used to generate PDX
(A) Age of patients at time of biopsy in 10-year increments. (B) Gender of patients. (C) 
Primary tumor type. (D) Site of tissue biopsy; categorized into primary melanoma, 
subcutaneous metastasis (SQ), lymph node metastasis (LN), distant metastasis to organs 
(Distant met), and brain metastasis (Brain). (E) Targeted kinase or immune checkpoint 
inhibitor therapies the patient had received before or during the biopsy was taken. Samples 
without available data were excluded from the analysis.
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Figure 3. Overview of PDX collection, immune therapy, targeted therapy resistant, and brain 
metastasis derived subsets
(A) All PDX and live frozen tissue samples sorted by driver mutations and therapy received 
by the patients. Driver mutations are dark blue for hotspot and light blue for non-hotspot 
mutation. PDX from patients progressed on targeted therapies are shades of purple, patients 
treated with immune checkpoint inhibitors are green: sequential, combination CTLA4+PD-1 
(IT combo), or combination with BRAF inhibition (TT/IT combo). Red indicates in vivo 
growth, presence of RPPA data, or a corresponding cell line. Samples that spontaneously 
metastasize to lungs in mice are red, yellow indicates no lung metastasis, white was not 
assessed. (B) Patients were treated with CTLA4 or PD-1 blocking therapy before, during, or 
after biopsy. Combination therapies are indicated. PDX are sorted by best response in the 
patients. Additional PDX with unknown response are not shown. (C) Genetic data of BRAF 
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(−BR) and BRAF/MEK (−CR) inhibitor-resistant PDX. Deleterious and likely deleterious 
mutations, homozygous loss, and high copy number gains (>5) are shown. Numbering after 
dash (1–4) indicate additional PDX available from the same patient. Asterisks indicate 
resistant PDX with available patient matched pre-therapy derived PDX.(D) Patient matched 
pre- and post-therapy PDX models. Progression free survival of patients treated with BRAF 
or BRAF/MEK inhibitor (x-axis). Columns are labeled with putative resistance mechanisms. 
(E) Genetic profile and therapy received of 22 PDX with available sequencing data out of 31 
total brain metastasis PDX. Deleterious and likely deleterious mutations, homozygous loss, 
and high copy number gains (>5) are shown. As an indication of PI3K pathway activation 
status RPPA levels of phosphorylated AKT are shown.
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Figure 4. Melanoma PDX metastasize spontaneously
(A) Animals were grafted with neonatal foreskin grafts and melanoma PDX cells were 
injected into established grafts. (B) Melanoma lesions formed in the human skin 
reconstructs. (C) Melanomas spontaneously metastasized to the mouse lungs from the 
human skin graft. H&E staining, and representative images. (D) Example of spontaneous 
micro-metastasis to lung. (E) Percentage of PDX that metastasize to lungs in more than 80% 
of animals from the subcutaneous tumor graft at the time point of maximal tumor volume. 
(F) Number of PDX with spontaneous lung metastasis compared to main mutational 
subgroups. (G) Luciferase transfected brain metastasis PDX injected s.c.. (H) Spontaneous 
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metastases to the mouse brain were imaged ex vivo after a latency of 120 days after survival 
surgery. (I) Percentage of IGF1R positive cells in PDX from naïve patients, from patients 
progressed on BRAF inhibitor (−BR), on BRAF inhibitor or BRAF/MEKi combination diet.
Krepler et al. Page 26
Cell Rep. Author manuscript; available in PMC 2017 December 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. PDX models in pre-clinical trials
(A) Computerized tomography scans of patient with early relapse on vemurafenib whose 
tumor was used to generated a PDX from a pre-therapy LN metastasis. Arrow indicates the 
lymph node metastasis biopsied, imaged before and 3 months on vemurafenib therapy. (B) 
The PDX bearing mice were fed a chemical additive diet containing PLX4720 200ppm as 
single agent or in combination with PD-0325901 7ppm (PLX+MEKi). The combination diet 
inhibited the PDX tumors’ growth, followed by early on-therapy relapse. (C) Ki67 staining 
indicating actively proliferating cells from tumor grafts on indicated treatments. (D) Two 
PDX models from patients relapsed on BRAF inhibition (n=10/group) were treated with 
chemical addictive diet containing the MEK inhibitor trametinib 2.1ppm (Tram), the PI3K 
beta inhibitor GSK231418 214.3ppm (GSK418) or the combination of both. (*) The 
combination significantly inhibited tumor growth over single agents in both models. (E) 
PDX model from a BRAF-V600E patient relapsed on vemurafenib (PFS 46 weeks, best 
response stable disease) that had an additional activating MEK mutation, TP53 WT, and a 
biomarker signature indicating sensitivity to p53 re-activation. PDX tumors (n=10/group) 
were treated with the ERK inhibitor BVD-523 50mg/kg twice daily oral gavage, the MDM2 
inhibitor CGM097 100mg/kg once daily oral gavage, or the combination of both. (E, right 
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panel) Single mouse growth curves of the BVD-523 + CGM treated group highlighting the 
heterogeneity of response in PDX models. While most tumors showed stable disease, two 
mice had early relapse and two mice had complete responses (CR). Dosing was stopped on 
day 38 (blue arrow) and the 2 CR mice showed regrowth of residual disease. (F) Twenty 
PDX of BRAFV600 mutant patients (naïve and BRAF inhibitor resistant), NRAS mutant, 
and BRAF-WT NRAS-WT (n=5 models each) were treated with the BET inhibitor 
BAY8097 10mg/kg once daily oral gavage (orange) or vehicle control (n=3/group, blue) in a 
rapid in vivo screen. Although variability within the PDX models was high, tumor growth 
velocity was decreased in a subset of models. Response was independent of mutation status. 
(G) IDH1 mutant PDX have increased 2-HG onco-metabolite levels in tumor tissue 
compared to IDH1 WT PDX.
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Figure 6. Protein pathway activation over time and in response to MAPK inhibition
WM4007 was generated from a pre-BRAF inhibitor therapy biopsy. (A) PDX growth curves 
for mice treated with PLX4720 (BRAFi) or PLX4720+PD-0325901 (BRAF/MEKi) diet 
started at time points indicated by black data points. (B) Protein expression change patterns 
identified in RPPA data with K means clustering. All proteins within each cluster are 
averaged and standard deviation shown. Clusters in bold had variation above 0.1 and were 
analyzed further. (C) Hierarchical clustering of RPPA data normalized to controls depicting 
the significant K means clusters along each time point. (D) Ingenuity Pathway Analysis 
(IPA) was used to assign proteins within each cluster into distinct biological processes. The 
top five significant gene ontology terms within each cluster are displayed with bars, top axis. 
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The percentage of each cluster’s proteins found within each biological functional category 
are displayed with orange dots, bottom axis.
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